On September 29, Summit Therapeutics PLC rose 17.39% in after-hours trading, trading at $18.17/share, with turnover of $7.45 million. The surge was fueled by a convergence of major clinical data catalysts for the company's core drug candidate, ivonescimab.

On the news front, partner Akeso's Phase III HARMONi-GI1 trial data has been selected for an ESMO Presidential Symposium late-breaking abstract oral presentation. The trial demonstrated that ivonescimab plus chemotherapy achieved statistically significant and clinically meaningful superiority in overall survival over AstraZeneca's durvalumab plus chemotherapy as a first-line treatment for advanced biliary tract cancer. The regimen also met key secondary endpoints of progression-free survival and objective response rate.

Additionally, updated HARMONi-2 data presented at WCLC showed ivonescimab monotherapy reduced the risk of death by 27% compared with pembrolizumab in PD-L1-positive non-small cell lung cancer, with consistent efficacy observed across both Western and Asian patient populations, reinforcing the drug's global applicability.

It is worth noting that Summit flagged going-concern risk in July due to insufficient cash to fund operations for the next year, and has pursued a $380 million stock offering plan to support ivonescimab's continued development.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)